Lv21
110 积分 2024-02-04 加入
Sacituzumab tirumotecan in previously treated metastatic triple-negative breast cancer: a randomized phase 3 trial
6小时前
待确认
Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer
6小时前
已完结
Sacituzumab Govitecan plus Pembrolizumab for Advanced Triple-Negative Breast Cancer
6小时前
已完结
Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial
6小时前
已完结
Sacituzumab Govitecan in Untreated, Advanced Triple-Negative Breast Cancer
7小时前
已完结
[Expert consensus on the diagnosis and clinical management of anaphylaxis]
1个月前
已完结
[Consensus on clinical diagnosis, treatment, and prevention of chemotherapy-induced neutropenia in China (2026 edition)]
3个月前
已完结
乳腺癌抗体药物偶联物不良反应管理指南（2025版）
3个月前
已完结
Pembrolizumab plus weekly paclitaxel in platinum-resistant recurrent ovarian cancer (ENGOT-ov65/KEYNOTE-B96): a multicentre, randomised, double-blind, phase 3 study
5个月前
已完结
Treatments for relapsed, BRCA-wild type, platinum-sensitive ovarian cancer: A systematic review and network meta-analysis
6个月前
已完结
皖公网安备34019202002308
